This clinical trial is focused on studying the effects of a new treatment for several types of advanced cancers, including Melanoma, Head and Neck Squamous Cell Carcinoma, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, and other Solid Tumors. The treatment being tested is a medication known by its code name, IPN01194, which is taken orally in the form of a hard capsule. The purpose of the study is to evaluate the safety and effectiveness of this medication when used alone in adult patients with these advanced cancers.
The study is divided into two phases. In the first phase, participants will receive different doses of IPN01194 to determine the safest and most effective dose. This phase will also monitor any side effects that may occur. In the second phase, the study will focus on how well the treatment works in reducing the size of the tumors. Participants will be closely monitored throughout the study to assess their response to the treatment and any changes in their condition.
Participants in the study will receive either the medication IPN01194 or a placebo. The study aims to gather information on how the body processes the medication and its impact on the tumors. This information will help researchers understand the potential benefits and risks of IPN01194 for treating these types of cancers. The study is expected to continue for several years to ensure comprehensive data collection and analysis.



France
Spain